solid insitu tumor of the body. In situ neoplasms
Conditions
Interventions
Intervention 1: Control group: Patients who receive only common chemotherapy agents without human recombinant Erythropoietin. Intervention 2: Intervention group: Anemic patients due to chemotherapy, r
Treatment - Drugs
Control group: Patients who receive only common chemotherapy agents without human recombinant Erythropoietin
Intervention group: Anemic patients due to chemotherapy, receiving human recombinant Erythropoietin,450 units per kilogram, Subcutaneously once in week for 12 weeks
Manufacturer company: Pooyesh Daro
Sponsors
Vice Chancellor for research of Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
1 Years to 15 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age of the patients, entering the study, should be beneath 15 years; The amount of Hemoglobin should be below 10 g/dL(gram per deciliter); Patients who are anemic due to chemotherapy, after they are diagnosed with solid insitu tumor; None of the patients have bone marrow involvement; Patients entering the study have normal kidney,liver,and lung function; Normal amounts of other blood-related parameters including retic.count, Serum ferritin, B12 vitamin in the serum, direct and indirect coombs tests, and ABG(Arterial Blood Gas); No history of blood transfusions in the last 1 month; No history of Erythropoietin consumption Exclusion criteria: Severe bleeding during the study; Hemolysis during the study due to any causes; The evidence of existing imapirment in kidney,liver,and lung function; Evidence of any serious side effects of Erythropoietin including thrombosis, increased systemic blood pressure, and polycythemia
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of hemoglobin increase. Timepoint: Weekly, until the end of the treatment. Method of measurement: g/dL(gram per deciliter) in blood tests.;The numbers and volume of blood transfusions. Timepoint: weekly blood test(hemoglobin amounts;transfusion of 10 ml/kg when hemoglobin is under 7 ml/dl). Method of measurement: Based on patients' hemoglobin and in mililiter. | — |
Secondary
| Measure | Time frame |
|---|---|
| The numbers of referring to the clinic. Timepoint: weekly. Method of measurement: using their clinic files. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmir ataollah hiradfar
Pediatric Health Research Center, Tabriz University of Medical Sciences
Outcome results
None listed